Baker Brothers Life Sciences Capital (GP), LLC
CIK 1307729 · last filed 2012-02-23
Baker Brothers Life Sciences Capital (GP), LLC is a corporate insider who has filed 62 SEC Form 4 insider transactions across 14 companies since 2007. The most recent filing shows the insider bought $9.6M of GHDX on Feb 23, 2012. Across all open-market trades the lifetime net is +$533.3M, making them a net buyer over the disclosed history. Current disclosed insider exposure totals $1.54B across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$1.54B
14
62
$533.25M
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| GENOMIC HEALTH INC (GHDX) Delisted | Director | 7,639,436 | — | — | $173.92M | 11 | 2012-02-23 |
| Ardea Biosciences, Inc./DE (RDEA) Delisted | Director | 4,922,226 | — | — | $44.72M | 1 | 2012-02-03 |
| INCY | Director | 12,213,272 | $116.69 | $1.43B | $232.64M | 16 | 2012-01-17 |
| SYNAGEVA BIOPHARMA CORP (GEVA) Delisted | Director | 5,077,676 | — | — | $0 | 1 | 2012-01-09 |
| VIROPHARMA INC (VPHM) Delisted | 10%+ Owner | 8,011,759 | — | — | $51.49M | 5 | 2011-08-25 |
| AUXILIUM PHARMACEUTICALS INC (AUXL) Delisted | 10%+ Owner | 6,112,357 | — | — | $0 | 1 | 2011-07-05 |
| BCRX | 10%+ Owner | 3,841,124 | $9.38 | $36.03M | $0 | 1 | 2011-07-05 |
| Seagen Inc. (SGEN) Delisted | Director | 11,119,820 | $228.74 | $2.54B | -$16.96M | 4 | 2010-05-27 |
| RPRX | 10%+ Owner | 1,345,866 | $59.02 | $79.43M | $1.78M | 1 | 2010-04-28 |
| Aceragen, Inc. (IDRA) Delisted | 10%+ Owner | 25,747 | $7.22 | $186.0K | -$8.70M | 6 | 2008-07-30 |
| ALLOS THERAPEUTICS INC (ALTH) Delisted | 10%+ Owner | 8,002,776 | — | — | $63.07M | 3 | 2008-05-27 |
| NEUROGEN CORP (NRGN) Delisted | Director | — | — | — | $0 | 1 | 2008-04-15 |
| TAPESTRY PHARMACEUTICALS, INC (TPPH) Delisted | 10%+ Owner | 1,821,429 | — | — | -$7.7K | 1 | 2008-04-08 |
| Aceragen, Inc. (IDP) Delisted | 10%+ Owner | 1,004,905 | — | — | -$8.69M | 6 | 2007-12-07 |
Recent Filings
62 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2012-02-23 | GENOMIC HEALTH INC (GHDX) Delisted | Buy (P) | +343,554 | $9.64M | EDGAR |
| 2012-02-10 | GENOMIC HEALTH INC (GHDX) Delisted | Buy (P) | +1,253,745 | $33.05M | EDGAR |
| 2012-02-03 | Ardea Biosciences, Inc./DE (RDEA) Delisted | Buy (P) | +2,630,484 | $44.72M | EDGAR |
| 2012-01-26 | — | Buy (P) | +1,501,956 | $27.17M | |
| 2012-01-17 | INCY | Buy (P) | +1,629,717 | $26.68M | EDGAR |
| 2012-01-09 | SYNAGEVA BIOPHARMA CORP (GEVA) Delisted | Grant (A) | +3,231,675 | $81.37M | EDGAR |
| 2012-01-03 | — | U | −20,008,014 | -$85.03M | |
| 2011-12-12 | INCY | Buy (P) | +1,210,563 | $16.18M | EDGAR |
| 2011-12-06 | — | Buy (P) | +264,591 | $4.08M | |
| 2011-12-01 | INCY | Buy (P) | +7,218,537 | $94.76M | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.